Progressive familial intrahepatic cholestasis type 2 (PFIC2) is an inherited liver disease characterized by impaired bile secretion, leading to accumulation of bile acids in the liver and systemic toxemia. This rare disease is caused by genetic mutations that affect biliary tract function. PFIC2 most often manifests itself in childhood, but its course is often progressive, which requires timely diagnosis and treatment. The disease is associated with disturbances in the extraction of bile acids from hepatocytes and their elimination through the bile ducts, which in severity can lead to liver cirrhosis and the need for organ transplantation.
History of the disease and interesting historical facts
Progressive familial intrahepatic cholestasis (PFIC) was first described in the mid-20th century, but type 2 was identified later when scientists began to study the genes involved in the disorder in detail. Interestingly, PFIC was first recognized as a distinct disorder after studies demonstrated the presence of genetic mutations that cause cholestasis. In 1996, a group of patients with features of PFIC were described, and since then there has been active research into its genetic basis and treatment options. Progress in understanding the mechanisms of the disease has led to a more in-depth analysis of not only PFIC, but also other biliary dysfunctions.
Epidemiology
From an epidemiological perspective, progressive familial intrahepatic cholestasis type 2 is a rare disease. The incidence of PFIC2 is estimated at 1 in 50,000-100,000 births. However, these figures may vary depending on the population and risk groups. Higher incidence rates are observed in certain ethnic groups and families where PFIC cases have been reported. This highlights the importance of family history and genetic counseling when planning a pregnancy. Certain regions may have a higher local incidence, suggesting a higher concentration of mutations that cause the disease.
Genetic predisposition to this disease
PFIC2 is caused by mutations in the ABCB11 gene, which encodes a protein associated with bile acid transport. This protein is the carrier responsible for the secretion of bile acids into bile. Mutations can be of various types, including point mutations, deletions, and inversions, which leads to functional deficiency of the protein and, as a consequence, to cholestasis. It is important to note that PFIC2 is inherited in an autosomal recessive manner, which means that mutations must be present in both parents for the disease to manifest. In addition, there are cases of spontaneous mutations, which can complicate the diagnosis.
Risk factors for the development of this disease
The risk of developing progressive familial intrahepatic cholestasis type 2 is increased in the following cases:
- Having a family history of cholestasis or other liver diseases, which may indicate a hereditary predisposition.
- Certain ethnic groups where the predisposition to the gene mutation is more common, such as Scandinavian peoples.
- Environmental conditions, such as occupational exposure to toxic substances that affect the liver.
- Pre-existing liver diseases that may worsen the course of PFIC2.
These factors are important to consider both when assessing the risk for future parents and when organizing health monitoring for children with relevant predispositions.
Diagnosis of this disease
PFIC2 diagnostics includes several stages:
- Main symptoms: itching, yellowing of the skin and mucous membranes, increased fatigue, enlargement of the liver and spleen.
- Laboratory tests: a blood biochemistry test showing elevated levels of bile acids, as well as transaminase and alkaline phosphatase.
- Radiological examinations: Ultrasound of the abdominal organs to assess the condition of the liver and bile ducts.
- Other types of disease diagnostics: genetic testing to detect mutations in the ABCB11 gene.
- Differential diagnosis: Other causes of cholestasis, such as viral hepatitis, autoimmune liver diseases, and other hereditary diseases, including other types of PFIC, must be excluded.
Thus, a comprehensive approach to PFIC2 diagnostics allows for an accurate diagnosis and selection of adequate treatment for the patient.
Treatment
Treatment of progressive familial intrahepatic cholestasis type 2 is multifactorial and depends on the severity of the disease:
- General treatment: a diet that limits fats and adds vitamins, especially fat-soluble ones.
- Pharmacological treatment: the use of ursodeoxycholic acid (UDCA) to reduce the level of bile acids in the blood and improve their excretion.
- Surgical treatment: In severe cases, tennis ball surgery or liver transplantation may be required, especially if cirrhosis develops.
- Other types of treatment: use of antipruritics to relieve the symptom of itching.
The challenge with PFIC2 is that effective treatment must be started early to prevent irreversible changes in the liver.
List of medications used to treat this disease
- Ursodeoxycholic acid (UDCA) is the mainstay of treatment for PFIC2.
- Antihistamines to relieve itching.
- Preparations of vitamins A, D, E and K to correct vitamin deficiencies.
- Cholestyramine – to combat the symptoms of cholestasis.
These medications help relieve symptoms and slow the progression of the disease.
Disease monitoring
Monitoring of progressive familial intrahepatic cholestasis includes regular examination of:
- Control stages: regular blood tests to monitor bile acid levels and liver enzymes.
- Forecast: Without treatment, PFIC2 can lead to liver cirrhosis and the need for a transplant.
- Complications: risk of developing death from liver failure and other potentially life-threatening conditions.
Careful monitoring allows for timely adjustments to treatment and assessment of the patient's condition.
Age-related features of the disease
The progression of PFIC2 varies depending on age group:
- In newborns, the disease can manifest itself in the first months of life with a clear clinical picture of cholestasis.
- In younger children, symptoms may be accompanied by growth and development of the deficiency, requiring more careful medical attention.
- In adolescents and adults, manifestations may be delayed, and the clinical picture may merge with other liver diseases, which leads to delayed diagnosis.
Genetic predisposition plays an important role, and lifelong monitoring of patients with this pathology is critical.
Questions and Answers
- What causes PFIC2 to develop? PFIC2 is caused by mutations in the ABCB11 gene, which is responsible for bile acid transport.
- How can PFIC2 be diagnosed? Diagnosis includes blood tests, liver ultrasound and genetic testing.
- What are the treatment options for PFIC2? Treatment includes pharmacological therapy with UDCA and, in some cases, surgery.
- What is the prognosis for patients with PFIC2? The prognosis depends on the severity, but without treatment cirrhosis and the need for a transplant are possible.
- How often should PFIC2 be monitored? Monitoring is recommended every 3-6 months, including tests and clinical examination.
This information provides a basis for increasing awareness of progressive familial intrahepatic cholestasis type 2 and highlights the importance of early diagnosis and prompt treatment.
